# Samsung Biologics Launches All-Cash Tender Offer to Acquire PolyPeptide for ~CHF 1.46B

> ma · REPORTED · 2026-07-20

Samsung Biologics launched an all-cash tender offer to acquire PolyPeptide Group for approximately CHF 1.46 billion (about $1.81 billion USD), aiming to significantly expand its peptide CDMO capabilities for peptide-based therapeutics used in metabolic and other diseases. The deal represents one of the largest life-science tools and CDMO transactions of mid-2026.

About Samsung Biologics: Samsung Biologics is a South Korean contract development and manufacturing organization (CDMO) providing large-scale biopharmaceutical manufacturing services to global biopharma clients; PolyPeptide Group is a leading peptide CDMO based in Switzerland.

- Company: Samsung Biologics
- Sector: biotech
- Primary source: https://tldrbio.tech/p/biotech-pharma-updates-july-20-2026

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.